Dear Shareholders,

I would like to express my gratitude on behalf of the Board of Directors for your investment and interest in Pfizer. Serving as your Lead Independent Director is a great privilege, and I am honored to work closely with the Chairman and my fellow Directors as we fulfill our fiduciary responsibilities to you, our valued shareholders.

Ensuring that we are well-informed about Pfizer's business performance is critical to the Board. Throughout 2023, we had regular discussions with management, which included reviewing the company's performance, corporate strategy, significant business initiatives, capital allocation priorities, and business development opportunities.

In addition, we worked closely with Pfizer's leaders to oversee significant initiatives for the company over the course of the year, including:

• The successful acquisition of Seagen, which will help propel Pfizer towards its goal of achieving world-class oncology leadership.
• The company’s reorganization of its R&D platform operations to further enhance its focus, speed, and execution in the field of oncology.
• Changes to the executive leadership team, detailed in this Proxy Statement.

Our Board is comprised of Directors with diverse skills and experiences that are highly relevant to Pfizer's business needs and overall strategy. We are proud of the Board's diverse composition, with each Director bringing a unique set of perspectives, experiences, and abilities to Pfizer. This diversity ensures that our Board functions effectively and efficiently. This year’s Proxy Statement includes enhanced disclosures that further highlight the skillsets of our Directors and how they align with Pfizer’s strategy. This disclosure was created in direct response to feedback received from our shareholders during the year.

The Board is also committed to its continuous improvement. We conduct annual evaluations to assess our performance and to ensure and enhance our overall effectiveness. In 2023, we engaged an external third-party provider to help conduct the annual Board and Committee evaluations, a process that proved to be highly productive and beneficial in providing us with constructive feedback.

In closing, we would like to express our appreciation to our shareholders for their confidence in Pfizer. We are grateful for the valuable feedback they have shared with the company, including in direct conversations with members of the Board, which meaningfully informs our governance and oversight practices.

Thank you for your continued support. Your vote is important, so please take the time to read the Proxy Statement and cast your vote.

Mr. Shantanu Narayen

Lead Independent Director